Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-02-21

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (INGENUS PHARMACEUTICALS, LLC)

View source ↗

Summary

FDA approved a supplemental application for buprenorphine and naloxone from Ingenus Pharmaceuticals, LLC, for this combination product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE AND NALOXONE)